<code id='6C671A37B8'></code><style id='6C671A37B8'></style>
    • <acronym id='6C671A37B8'></acronym>
      <center id='6C671A37B8'><center id='6C671A37B8'><tfoot id='6C671A37B8'></tfoot></center><abbr id='6C671A37B8'><dir id='6C671A37B8'><tfoot id='6C671A37B8'></tfoot><noframes id='6C671A37B8'>

    • <optgroup id='6C671A37B8'><strike id='6C671A37B8'><sup id='6C671A37B8'></sup></strike><code id='6C671A37B8'></code></optgroup>
        1. <b id='6C671A37B8'><label id='6C671A37B8'><select id='6C671A37B8'><dt id='6C671A37B8'><span id='6C671A37B8'></span></dt></select></label></b><u id='6C671A37B8'></u>
          <i id='6C671A37B8'><strike id='6C671A37B8'><tt id='6C671A37B8'><pre id='6C671A37B8'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:9
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Readout LOUD podcast: ASCO preview, a Duchenne trial failure
          Readout LOUD podcast: ASCO preview, a Duchenne trial failure

          WhichpresentationsareworthcatchingatASCOthisweekend?Whatisexon-skipping?Andhowdoyoupronouncebronchie

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          NIH documents show early flaws of $1.6 billion long Covid program

          ThestageattheLincolnMemorialinWashingtonforaMarch15rallytoraiseawarenessforlongCovid.RobbHillforTheS